Related Experiment Video
Updated: Mar 2, 2026
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological
Aleksandra Twarda-Clapa1, Sylwia Krzanik1, Katarzyna Kubica2
1Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University , Gronostajowa 7, 30-387 Cracow, Poland.
Abstract:
The tumor suppressor protein p53, the "guardian of the genome", is inactivated in nearly all cancer types by mutations in the TP53 gene or by overexpression of its negative regulators, oncoproteins MDM2/MDMX. Recovery of p53 function by disrupting the p53-MDM2/MDMX interaction using small-molecule antagonists could provide an efficient nongenotoxic anticancer therapy. Here we present the syntheses, activities, and crystal structures of the p53-MDM2/MDMX inhibitors based on the 1,4,5-trisubstituted imidazole scaffold which are appended with aliphatic linkers that enable coupling to bioactive carriers. The compounds have favorable properties at both biochemical and cellular levels. The most effective compound 19 is a tight binder of MDM2 and activates p53 in cancer cells that express the wild-type p53, leading to cell cycle arrest and growth inhibition. Crystal structures reveal that compound 19 induces MDM2 dimerization via the aliphatic linker. This unique dimerization-binding mode opens new prospects for the optimization of the p53-MDM2/MDMX inhibitors and conjugation with bioactive carriers.
Insights
Scientists developed new small-molecule inhibitors targeting the p53-MDM2/MDMX interaction. Compound 19 effectively reactivates tumor suppressor p53 in cancer cells, halting tumor growth and offering a novel anticancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The tumor suppressor protein p53 is crucial for genomic stability.
- p53 is frequently inactivated in cancers via TP53 mutations or MDM2/MDMX overexpression.
- Restoring p53 function presents a promising anticancer strategy.
Purpose of the Study:
- To synthesize and characterize novel small-molecule inhibitors of the p53-MDM2/MDMX interaction.
- To explore the potential of these inhibitors as nongenotoxic anticancer therapeutics.
- To investigate the structural basis for inhibitor activity and potential for conjugation.
Main Methods:
- Synthesis of 1,4,5-trisubstituted imidazole derivatives.
- Biochemical and cellular assays to evaluate inhibitor activity.
- X-ray crystallography to determine binding modes and structural insights.
Main Results:
- Developed imidazole-based inhibitors with favorable biochemical and cellular properties.
- Compound 19 demonstrated potent binding to MDM2 and activated wild-type p53 in cancer cells.
- Compound 19 induced MDM2 dimerization through its aliphatic linker, a novel binding mechanism.
Conclusions:
- Small-molecule inhibition of the p53-MDM2/MDMX interaction is a viable anticancer strategy.
- Compound 19 shows significant potential for reactivating p53 and inhibiting tumor growth.
- The unique dimerization-binding mode offers new avenues for optimizing p53-MDM2/MDMX inhibitors.
More Related Videos
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
02:23Abnormal Proliferation